[{"id":"6f307756-0908-4621-b9f3-65923112cc09","acronym":"SHINE ","url":"https://clinicaltrials.gov/study/NCT01776840","created_at":"2021-01-18T07:50:07.776Z","updated_at":"2024-07-02T16:34:37.245Z","phase":"Phase 3","brief_title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01776840 - SHINE ","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-06-07"},{"id":"51c7eecc-8aaa-40fe-a0b8-2cc5f7db6669","acronym":"","url":"https://clinicaltrials.gov/study/NCT05976763","created_at":"2023-08-04T17:10:02.415Z","updated_at":"2024-07-02T16:35:01.638Z","phase":"Phase 3","brief_title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT05976763","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 421","initiation":"Initiation: 09/08/2023","start_date":" 09/08/2023","primary_txt":" Primary completion: 08/31/2038","primary_completion_date":" 08/31/2038","study_txt":" Completion: 08/31/2038","study_completion_date":" 08/31/2038","last_update_posted":"2024-05-23"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"25e24245-9e4c-4767-b5e7-b2e9ba8446f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983965","created_at":"2023-08-09T14:09:35.762Z","updated_at":"2024-07-02T16:35:05.238Z","phase":"Phase 1","brief_title":"Study of Tazemetostat in Lymphoid Malignancies","source_id_and_acronym":"NCT05983965","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CD4","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-08"},{"id":"92a6a0af-b961-4dcd-9f55-a9a03ecbdb52","acronym":"TRANSCEND-NHL-001","url":"https://clinicaltrials.gov/study/NCT02631044","created_at":"2021-01-17T17:40:23.377Z","updated_at":"2024-07-02T16:35:12.562Z","phase":"Phase 1","brief_title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","source_id_and_acronym":"NCT02631044 - TRANSCEND-NHL-001","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 387","initiation":"Initiation: 01/06/2016","start_date":" 01/06/2016","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 05/10/2024","study_completion_date":" 05/10/2024","last_update_posted":"2024-03-27"},{"id":"d8a4d573-54c5-44f7-aa60-0be67e158582","acronym":"LYMA-101","url":"https://clinicaltrials.gov/study/NCT02896582","created_at":"2021-01-18T14:12:53.282Z","updated_at":"2024-07-02T16:35:14.422Z","phase":"Phase 2","brief_title":"Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","source_id_and_acronym":"NCT02896582 - LYMA-101","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20 • CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression • CCND1 expression","tags":["CD20 • CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cytarabine • Gazyva (obinutuzumab) • etoposide IV • dexamethasone • carmustine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-03-15"},{"id":"fd1666a8-c3ef-43e6-9207-5e19e3282d91","acronym":"NIREC","url":"https://clinicaltrials.gov/study/NCT05289648","created_at":"2022-03-21T19:56:04.999Z","updated_at":"2024-07-02T16:35:21.231Z","phase":"Phase 1","brief_title":"Niraparib in High-grade Endometrial Cancer Trial","source_id_and_acronym":"NCT05289648 - NIREC","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","biomarkers":" TP53 • CCND1 • CASP3 • CDKN1A","pipe":" | ","alterations":" CCND1 expression","tags":["TP53 • CCND1 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-02-01"},{"id":"9c600949-8873-463d-a2fa-8de9099f93f7","acronym":"PrE0405","url":"https://clinicaltrials.gov/study/NCT03834688","created_at":"2021-01-18T18:56:00.049Z","updated_at":"2024-07-02T16:35:22.524Z","phase":"Phase 2","brief_title":"Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age","source_id_and_acronym":"NCT03834688 - PrE0405","lead_sponsor":"PrECOG, LLC.","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/13/2020","start_date":" 01/13/2020","primary_txt":" Primary completion: 10/20/2022","primary_completion_date":" 10/20/2022","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-01-23"},{"id":"397f0e26-37b8-4a9d-b120-14ffdb427e26","acronym":"","url":"https://clinicaltrials.gov/study/NCT03327064","created_at":"2021-01-18T16:25:49.496Z","updated_at":"2024-07-02T16:35:25.146Z","phase":"Phase 1/2","brief_title":"A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer","source_id_and_acronym":"NCT03327064","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UAB30"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2023-12-27"},{"id":"266a2712-9c1f-4bc2-b88c-002f9d951d7d","acronym":"GOG-3039","url":"https://clinicaltrials.gov/study/NCT04393285","created_at":"2023-12-13T16:16:37.842Z","updated_at":"2024-07-02T16:35:26.346Z","phase":"Phase 2","brief_title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","source_id_and_acronym":"NCT04393285 - GOG-3039","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20","pipe":" | ","alterations":" CCND1 expression • CCND1 mutation","tags":["ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/10/2020","start_date":" 10/10/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-13"},{"id":"3d78b9c9-76dd-4802-b171-aa3cd7379f4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02290145","created_at":"2021-01-18T10:47:43.754Z","updated_at":"2024-07-02T16:35:28.309Z","phase":"Phase 2","brief_title":"Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage","source_id_and_acronym":"NCT02290145","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression • CCND1 expression • CCND1-H","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND1 expression • CCND1-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-11-22"},{"id":"7122b640-e8c3-4f66-a9cf-75e23b76f6c1","acronym":"WinPro","url":"https://clinicaltrials.gov/study/NCT03906669","created_at":"2021-01-18T19:13:54.012Z","updated_at":"2024-07-02T16:35:28.353Z","phase":"Phase 2","brief_title":"A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.","source_id_and_acronym":"NCT03906669 - WinPro","lead_sponsor":"St Vincent's Hospital","biomarkers":" HER-2 • BCL2 • AR • CCND1 • FOXA1 • CASP3","pipe":" | ","alterations":" HER-2 negative • CCND1 expression","tags":["HER-2 • BCL2 • AR • CCND1 • FOXA1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-11-22"},{"id":"5344b2f6-be19-468a-abe6-7dd10ed181d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04807881","created_at":"2021-03-19T15:59:16.539Z","updated_at":"2024-07-02T16:35:30.105Z","phase":"Phase 1","brief_title":"Phase Ib Clinical Study of Keynatinib","source_id_and_acronym":"NCT04807881","lead_sponsor":"Medolution Ltd.","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression • CCND1 expression • CCND1-H","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND1 expression • CCND1-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e keynatinib (TL007)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 10/10/2027","primary_completion_date":" 10/10/2027","study_txt":" Completion: 04/10/2028","study_completion_date":" 04/10/2028","last_update_posted":"2023-11-07"},{"id":"22596f08-9a13-45d8-aa0e-b548af9dec06","acronym":"","url":"https://clinicaltrials.gov/study/NCT02728531","created_at":"2021-01-18T13:21:23.644Z","updated_at":"2024-07-02T16:35:30.887Z","phase":"Phase 1","brief_title":"Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT02728531","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD20 • CCND1 • CD34","pipe":" | ","alterations":" CD20 expression • CD19 expression • CCND1 expression","tags":["CD20 • CCND1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • bendamustine • Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/18/2016","start_date":" 04/18/2016","primary_txt":" Primary completion: 01/16/2019","primary_completion_date":" 01/16/2019","study_txt":" Completion: 08/16/2023","study_completion_date":" 08/16/2023","last_update_posted":"2023-11-01"},{"id":"e089e3f8-f160-47a9-a0b8-746650c303a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861050","created_at":"2023-05-16T17:06:41.960Z","updated_at":"2024-07-02T16:35:30.746Z","phase":"Phase 1/2","brief_title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05861050","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • CDKN2A • CCND1 • KMT2D • NOTCH2 • SOX11 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr t(11;14) • KMT2D mutation • CCND1 expression • SOX11 expression","tags":["TP53 • CDKN2A • CCND1 • KMT2D • NOTCH2 • SOX11 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(11;14) • KMT2D mutation • CCND1 expression • SOX11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-11-01"},{"id":"49b9bdb6-a946-472f-8310-c49daa2ab094","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495828","created_at":"2022-08-10T12:55:35.171Z","updated_at":"2024-07-02T16:35:31.522Z","phase":"","brief_title":"Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT05495828","lead_sponsor":"Peking University People's Hospital","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/10/2023","start_date":" 11/10/2023","primary_txt":" Primary completion: 12/10/2024","primary_completion_date":" 12/10/2024","study_txt":" Completion: 03/10/2025","study_completion_date":" 03/10/2025","last_update_posted":"2023-10-26"},{"id":"bb01e540-077e-40c1-931c-07315b7ce5c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04115631","created_at":"2021-01-18T20:07:06.177Z","updated_at":"2024-07-02T16:35:45.128Z","phase":"Phase 2","brief_title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT04115631","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" CCND1 • CD34","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CCND1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 12/13/2019","start_date":" 12/13/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2023-06-22"},{"id":"82531c2c-bcb7-42e2-9ec8-ce047667334c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04802590","created_at":"2021-03-17T15:57:39.090Z","updated_at":"2024-07-02T16:35:53.029Z","phase":"Phase 2","brief_title":"Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT04802590","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20 • CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression • CCND1 expression","tags":["CD20 • CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 01/24/2022","start_date":" 01/24/2022","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 09/30/2031","study_completion_date":" 09/30/2031","last_update_posted":"2023-03-17"},{"id":"8b764d74-e563-4c46-9e6c-33001c101645","acronym":"","url":"https://clinicaltrials.gov/study/NCT05051891","created_at":"2021-09-21T11:53:41.573Z","updated_at":"2024-07-02T16:36:02.613Z","phase":"Phase 3","brief_title":"A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma","source_id_and_acronym":"NCT05051891","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" CCND1 expression","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 356","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2022-10-12"},{"id":"c70be74b-2caf-4912-96ba-c804e6129925","acronym":"NeoART","url":"https://clinicaltrials.gov/study/NCT02633098","created_at":"2021-01-18T12:48:25.777Z","updated_at":"2024-07-02T16:36:02.617Z","phase":"Phase 2","brief_title":"A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer","source_id_and_acronym":"NCT02633098 - NeoART","lead_sponsor":"St George's, University of London","biomarkers":" KRAS • BRAF • MYC • CCND1 • CD31 • PECAM1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • MYC expression • CCND1 expression","tags":["KRAS • BRAF • MYC • CCND1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • MYC expression • CCND1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/26/2017","start_date":" 04/26/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2022-10-12"},{"id":"38e3841f-945a-442c-9886-2b12399f1da4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02736617","created_at":"2021-01-18T13:24:12.076Z","updated_at":"2024-07-02T16:36:18.852Z","phase":"Phase 2","brief_title":"Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma","source_id_and_acronym":"NCT02736617","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" CCND1 • CD5","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 07/05/2016","start_date":" 07/05/2016","primary_txt":" Primary completion: 06/02/2021","primary_completion_date":" 06/02/2021","study_txt":" Completion: 06/02/2021","study_completion_date":" 06/02/2021","last_update_posted":"2022-01-05"},{"id":"42fe226f-3bc9-4d6c-b7b0-8d4cf40b3da9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04049227","created_at":"2021-01-18T19:51:28.388Z","updated_at":"2024-07-02T16:36:30.778Z","phase":"Phase 1","brief_title":"Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer","source_id_and_acronym":"NCT04049227","lead_sponsor":"Northwestern University","biomarkers":" PTEN • CCND1","pipe":" | ","alterations":" PTEN mutation • CCND1 expression","tags":["PTEN • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 08/12/2019","start_date":" 08/12/2019","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2021-05-03"},{"id":"d9db1684-d818-43fa-9529-2574c116f261","acronym":"Polen","url":"https://clinicaltrials.gov/study/NCT02506816","created_at":"2021-01-18T12:06:01.875Z","updated_at":"2025-02-25T15:06:43.322Z","phase":"","brief_title":"Preoperative Olaparib Endometrial Carcinoma Study (POLEN)","source_id_and_acronym":"NCT02506816 - Polen","lead_sponsor":"MedSIR","biomarkers":" PTEN • ARID1A • CCND1 • HIF1A • PARP1 • CASP3","pipe":" | ","alterations":" CCND1 expression • HIF1A expression","tags":["PTEN • ARID1A • CCND1 • HIF1A • PARP1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-11-30"},{"id":"a08199e1-d4ac-4363-90a1-41a28d158504","acronym":"UT-201501;ATTCK-20-2t","url":"https://clinicaltrials.gov/study/NCT02776813","created_at":"2021-01-18T13:36:59.779Z","updated_at":"2024-07-02T16:36:47.201Z","phase":"Phase 1","brief_title":"Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma","source_id_and_acronym":"NCT02776813 - UT-201501;ATTCK-20-2t","lead_sponsor":"Cogent Biosciences, Inc.","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • ACTR087"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 02/12/2020","primary_completion_date":" 02/12/2020","study_txt":" Completion: 02/12/2020","study_completion_date":" 02/12/2020","last_update_posted":"2020-03-31"}]